🧪 Advancing care for systemic mastocytosis starts with the latest evidence happening at #ASH26! Explore clinical trial findings, assess disease control, and enhance interprofessional treatment decisions. 🚀 Stay informed—join this educational activity! mdsc.pe/4yfvJ3h

🔍 MDS treatment decisions are becoming increasingly precise. Discover how cytogenetic and molecular characteristics can guide care, examine trial data 🧪 across the disease continuum & strengthen team-based management of treatment complexities. ⚡ Turn evolving evidence into action—join us! mdsc.pe/4r4FVcQ #ASH26

🔬 How can you optimize care for patients with newly diagnosed multiple myeloma ? Explore clinical evidence for transplant-eligible and ineligible patients, personalized treatment strategies, and the importance of collaborative care. 💡 Strengthen your clinical decision-making—join this educational activity! mdsc.pe/3U0ktts #ASH26

🗣️ Better labs matter. So do better days. Discover how to navigate the move from first- to second-line PBC therapy, address symptoms and 🌿 biochemical parameters, and develop patient-centric management strategies. 🔬 Put the whole patient at the heart of PBC care—register today! mdsc.pe/4iRKdl

🧬 In MDS, the molecular details matter. Explore cytogenetic and molecular features that inform clinical decisions, review evolving 🔬 trial data & translate the evidence into treatment choices across the disease continuum. 🩸 Sharpen your MDS strategy! mdsc.pe/4r4FVcQ #ASH26

🔍 Could PFIC or ALGS be hiding in your adult patients? Strengthen recognition & diagnosis, navigate the appropriate use of targeted therapies 🧬 & discover how interprofessional care can address their multisystem impact. 🤝 Be ready for these cases— mdsc.pe/4h8ewDH

🎯 Optimizing prostate cancer care starts with informed treatment decisions! Explore ARPI trial data, identify candidates for mHSPC and nmCRPC therapies, and learn when to intensify treatment. 📈 Strengthen your knowledge—learn more! mdsc.pe/4hLfKoS #ESMO

🔄 Sequence matters in HER2-positive GEA. Dive into emerging anti-HER2 evidence, navigate treatment decisions across the patient journey & strengthen strategies for managing diarrhea and optimizing safety. 🤝 Advance your GEA approach—save your spot! mdsc.pe/4hk4FcR

🧪 Systemic mastocytosis care is evolving across the disease spectrum. Explore recent clinical trial data, identify patients who may benefit from advanced treatment & ✨ evaluate whether disease control is truly adequate. 🧭 Stay ahead of SM care—register today! mdsc.pe/4yhO28u #ASH26

🔬 How are emerging therapies shaping the future of platinum-resistant ovarian cancer (PROC) care? Join @BanerjeeSusana to examine the latest ADC evidence, treatment safety, and biomarker-driven decisions. 💡 Explore the latest insights—learn more! mdsc.pe/4dRs3xo #ESMO2026 #ESMO

🪁 There’s more to hemophilia care than bleed counts. Explore clinically meaningful differences between therapies and learn how to match treatment to each patient’s disease, priorities, and needs. 🧭 Strengthen shared decisions across the care team. Join us! mdsc.pe/4irU5mb #ASH26

💊 Optimizing R/R DLBCL treatment requires evidence-based decisions! Explore bispecific antibody trial findings, treatment sequencing, and practical strategies for community-based care. 🎯 Enhance your expertise! mdsc.pe/4ex4Q3I #ASH26

🎯 Personalizing PROC treatment starts with the right evidence! Join @BanerjeeSusana to explore novel ADCs, emerging combination therapies, and biomarker-guided treatment decisions. 💡 Learn more! mdsc.pe/4dRs3xo

SAVE THE DATE 🗓️ Join Dr. Nabil F. Saba & Jarushka Naidoo to explore clinical care insights on NTRK fusions across lung & thyroid cancer. 🗓️ Oct 29 ⏰ 11:30am EST 🔗 mdsc.pe/4k9208O #Oncology #NTRKFusions

🔬 Novel ADCs are advancing breast cancer care! 🧬 @JavierCortesMD, @RebeccaDSing & @stolaney1 highlight emerging trial data, biomarker-driven strategies, and evolving treatment approaches across breast cancer subtypes. 🎯 mdsc.pe/3TKIKni #ESMO

🔬 How are emerging therapies shaping the future of platinum-resistant ovarian cancer (PROC) care? Join @BanerjeeSusana to examine the latest ADC evidence, treatment safety, and biomarker-driven decisions. 💡 Explore the latest insights—learn more! mdsc.pe/4dRs3xo #ESMO2026 #ESMO

💊 When should prostate cancer treatment be intensified? Examine ARPI clinical evidence and patient selection considerations across mHSPC and nmCRPC. Join expert @cgratzke! 🧠 Sharpen your decision-making! mdsc.pe/4hLfKoS #ESMO

📈 From clinical trials to treatment decisions! Explore how ARPI data can inform patient selection and treatment intensification strategies in mHSPC and nmCRPC. ✨ Strengthen your knowledge! mdsc.pe/4hLfKoS #ESMO

🧬 What's next in platinum-resistant ovarian cancer (PROC) care? Join @BanerjeeSusana to explore emerging ADCs, novel treatment combinations, and biomarker-guided strategies. 🔍 Expand your knowledge—learn more! mdsc.pe/4dRs3xo #ESMO2026 #ESMO

🧪 Advancing care for systemic mastocytosis starts with the latest evidence happening at #ASH26! Explore clinical trial findings, assess disease control, and enhance interprofessional treatment decisions. 🚀 Stay informed—join this educational activity! mdsc.pe/4yfvJ3h